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Summary. The enantiomeric [1,2-bis(4-fiuorophenyl)eth- 
ylenediamine]dichloroplatinum(II) complexes were syn- 
thesized and tested on the hormone-sensitive human 
MCF7 breast cancer cell line and on the P388 leukemia 
of the mouse. They showed a strong and comparable ac- 
tivity on both tumor models. 
Key words: (R,R)- and (S,S)-[1,2-bis(4-fluorophenyl)eth- 
ylenediamine]dichloroplatinum(II) Synthesis - MCF7 
breast cancer cell line P388 mutine leukemia 
Introduction 
R,S- and R,R/ S,S-configurated diaqua[1,2-bis(4-fluoro- 
phenyl)ethylenediamine]platinum(II) sulfates and ni- 
trates (1-4) display a strong growth inhibition of the hor- 
mone-dependent MXT-M3.2 mammary carcinoma of 
the mouse (Reile et al. 1990 b). Their effect is independent 
of the ligand configuration, R,S (meso) or R,R/S,S (race- 
mate), and identical with that of cisplatin. In contrast to 
cisplatin, however, the diaqua [1,2-bis(4-fluorophenyl)- 
ethylenediamine]platinum(II) sulfates and nitrates cause 
a strong decrease in uterine weight of the adult but 
not of the juvenile mouse. This phenomenon is thought 
to be a consequence of an interference in the steroid bio- 
synthesis. Therefore we assume that [1,2-bis(4-fluorophe- 
nyl)ethylenediamine]platinum(II) complexes exert their 
mammary-tumor-inhibiting properties by a decrease of 
the estrogen and progesterone level as well as by an inter- 
ference with DNA replication in analogy to the mode of 
action of cisplatin. In fact, compound 2, with R,R/S,S 
configuration, inhibits the [3H]thymidine incorporation 
into hormone-independent human MDA-MB231 breast 
cancer cells to the same extent as cisplatin (Reile et al. 
* Dedicated to Professor Dr. D. Schm/ihl on the occasion of his 
65th birthday 
Abbreviations. R,R/S,S, racemate; R,S, meso 
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1990b). Compound 1, with R,S-configuration, is some- 
what less active in this experiment. The same results 
were seen with the analogous dichloroplatinum(II) com- 
plexes (Reile et al. 1990b). Platinum complexes that do 
not only act on the hormone-dependent bu also on the 
hornaone-independent mammary carcinoma (i.e. es- 
trogen-receptor-positive and-negative, respectively) are 
of great therapeutic nterest, since they delay or perhaps 
prevent he development of resistance, which originates 
from estrogen-receptor-negative mammary carcinoma 
clones. 
The aim of this work was to show whether the effect 
of one enantiomer of [1,2-bis(4-fluorophenyl)ethylenedi- 
amine]dichloroplatinum(II) is superior to that of its 
racemic mixture (compound 8). In the following we will 
describe the resolution of compound 8 into its enan- 
tiomers 9 and 10, the determination of the absolute con- 
figuration by circular dichroism (CD) spectroscopy and 
the testing on the hormone-sensitive human MCF7 
breast cancer cell line and on the P388 leukemia of the 
mouse. 
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8a, 8 R.R/S.5 
9a, 9 R.R 
10a, 10 S,S 
8, 9, 10 
Table 1. 1 H-NMR data of enantiomeric [1,2-bis(4-fluorophenyl)ethylenediamine]dichloroplatinum(II) complexesand of their ligands 
Compound Configuration R Leaving Counter 
group (L) ion 
R R 1 R,S 4~F OH 2 SO 4 
~ 2 R,R/S,S 4-F OH 2 804 
3 R,S 4-F OH 2 (NO3) 2 
4 R,R/S,S 4-F  OH 2 (NO3) 2 
5 R,R/S,S 3-OH C1 - 
HC CH 6 R,R/S,S 4-OH C1 - / \ 
H2 N NH 2 7 R,S 4-F C1 - 
~pt /  8 R,R/S,S ZbF Cl - 
9 R,R 4-F C1 - 
L / ~L 10 S,S 4-F C1 - 
Compound 5 (ppm) (tetramethylsilane, internal) 
Aromatic H CH (benzylic) NH 
9a a 6.90-6.99 (m, 4 H) 4.01 (s, 2 H) 
7.13-7.20 (m, 4 H) 
lOa" 6.89-6.99 (m, 4 H) 4,01 (s, 2 H) 
7.13-7.19 (m, 4 H) 
9a. 2HCL b 7.01-7.61 (m, 8 H) 5.2 (s, 2 H) 
lOa. 2HC1 b 6.98 7.56 (m, 8 H) 5.2 (s, 2 H) 
9 c 7.03-7.10 (m, 4 H) 5.2 (m, br, 2 H) 
7.75-7.80 (m, 4 H) 
10 c 7.03-7.10 (m, 4 H) 5.2 (m, br, 2 H) 
7.75 7.81 (m, 4 H) 
1.6 (s, br, 4 H) 
1.6 (s, br, 4 H) 
6.0 (m, br, 2 H) 
6.4%6.52 (m, 2 H) 
5.926.03 (m, 2 H) 
5.49-6.53 (m, 2 H) 
a CDC13, 250 MHz 
b CD3OD, 60 MHz 
c dv_dimethylformamide ' 250 MHz 
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Mater ia l s  and methods  
Chem&try 
The synthesis of (• (8a) 
has been described in one of our previous publications (Miiller et al. 
1989). Since it turned out that neither ethylenediamine ligands nor 
dichloroplatinum(II) complexes were appreciably resolved by 
HPLC on triacetylcellulose, compound 8a was resolved in MeOH 
by fractional crystallization ofits diastereomeric salts with optically 
active tartaric acid (method A). This procedure leads to complete 
enantiomeric purity of the diamines [(+)9 a and ( - )10 ai. For ana- 
lytical characterization, the oily bases were transformed into their 
solid dihydrochlorides (+)9a.2HC1 and (-)10a.2HC1 (method 
B). The enantiomeric [1,2-bis(4-fluorophenyl)ethylenediamine] 
platinum(II) complexes [(+)9 and (-)10] were synthesized by 
reacting K2PtC14 with (+)9a.2HC1 and (- ) I0a.2HC1, respec- 
tively, in aqueous olution (method C). 1H-NMR data and elemen- 
tal analyses of these substances are listed in Tables 1 and 2. 
The absotute configuration of the enantiomeric [1,2-bis(4- 
fluorophenyl)ethylenediamine]dichloroplatinum(II) complexes (9 
Table 2. Enantiomeric [1,2-bis(4-fluorophenyl)ethylenediamine] 
dichloroplatinum(II) complexes, 9 and 10 and their ligands 
9a. 2HC1 and lOa - 2HCI: elemental nalyses 
Com- C (%) H (%) N (%) 
pound 
Calcd. Found Calcd. Found Calcd. Found 
9a. 2HC1 52,4 52.4 5.02 4.91 8.7 8.5 
lOa. 2HC1 52.4 4.87 8.5 
9 32.7 33.2 2.75 2.83 5.5 5.3 
10 33.0 2.90 5.2 
and 10) was determined by comparison of their CD spectra with 
those of (+)(R,R)- and (-)(S,S)-dichloro[l,2-diphenylethylenedi- 
amine] platinum(II), the structural ssignment ofwhich derives from 
the known absolute configuration of (+)-l,2-diphenylethylenedi- 
amine (R,R) (Meric and Vigneron 1974). In analogy to the 3- and 
4-hydroxy-substituted ( _+ )-dichloro[1,2-diphenylethylenediamine] 
platinum(II) complexes 5 (Jennerwein et al. 1989a) and 6 (Wappes 
et al. 1984), the dextrorotatory enantiomer of the (• 
fluorophenyl)ethylenediamine]dichloroplatinum(II) (8) has the R,R 
F F ~~ cHN 
/ \ 
H2N NH2 3.12 2.95 
+ 
F3Cs /OH (+) I 
H',,IIC 3.12 
(si _ _  
6.3 equivalents 2.96 
Fig. 1 .1H-NMR benzyl signals of ligands in CDC13 at 250 MHz in 
the presence of 6.3 equivalents of an optically active auxiliary and 
ofa small amount of D20. Top: (+)8a shows singlets for both en- 
antiomers. Center: (+)9a shows one singlet only, i.e. an enantio- 
meric purity of approx. 100%. Bottom: ( - ) !0 a shows another sing- 
let, exclusively (i.e. purity approx. 100%). 
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(compound 9) and the levorotatory enantiomer S,S configuration 
(compound 10). 
( +_ )- 1,2-Bis (4-fluorophenyl) ethylenediamine [8ai. The synthesis 
of 8a has been reported by Mfiller et al. (1989). 
( + )- and ( - ) -1,2-Bis (4-fluorophenyl) ethylenediamine [ ( + ) 9 a 
and ( - ) lOa],  method A. Compound 8a (7.49g, 30.17 mmol), 
dissolved in 35 ml MeOH, was added to the solution of L(+)-tar- 
taric acid (13.58 g, 90.51 mmol) in 85 ml MeOH and boiled for 
10 min. The solution was allowed to cool slowly. The tartrate of 
( - )10a  crystallized at room temperature and was recrystallized 
from MeOH several times. The free base was obtained by treatment 
with 5% NaOH, extraction with CH2C1 z, washing with H20 and 
drying over MgSO4. The product was a colorless oil, yield 28%, 
[oE]216: - -110 ,  c= 1.0, MeOH, enantiomeric purity approximately 
100%. From the mother liquors of the precipitates the diamine, 
which contains an excess of (+)9a, was isolated as free base and 
purified in the saine manner by crystallization of the D( -  )-tartrate. 
The diamine was a colorless oil, yield 34%, [oE]sz416 = + 109, c = 1.0, 
MeOH, enantiomeric purity: approximately 100%. The enantio- 
meric purity was determined by 1H-NMR spectroscopy (250 MHz) 
by means of the formation of diastereomeric complexes with (S)-I- 
(9-anthryl)-2,2,2-trifluoroethanol. The molar ratio of this alcohol to 
compound (+)9a and compound ( - )10a,  respectively, was 6.3 
[10.24mg (+)9a or (-)10a, 71.87mg (S)-l-(9-anthryl)-2,2,2-tri- 
fluoroethanol and two drops DzO in 0.5 ml CDCl~]. The enantio- 
meric purity was established by the integral ratio of the two singlets 
for the benzylic protons. The absorption band of compound 
( - )10 a is shifted to higher field (6 = 2.96 ppm) than that of (+)9 a 
(6 = 3.12 ppm) (Fig. 1). 
( + )-l,2-Bis(4-fluorophenyl)ethylenediaminedihydrochloride 
[(+)9a.2HC1], method B. To compound (+)9a, dissolved in a 
small amount of MeOH, ethereal HC1 was added ropwise under ice 
cooling. After addition of Et20 to tarnish, the mixture was allowed 
to stand in the refrigerator. The precipitate was sucked off. Color- 
less crystals, re.p. 241.0 241.5 ~ C (decomp.), yield 50%, [oE]2] 6= + 
49, c = 1.0, MeOH. 
MHz) spectrometer and 1H-NMR spectra of the platinum com- 
plexes with a Bruker PFT-NMR spectrometer WM 250 at 
250 MHz. Elemental analyses were carried out by the Microlabora- 
tory of the University of Regensburg. The polarimeter was a Perkin- 
Elmer 241 MC (Perkin-Elmer, Uberlingen, FRG). 
Biological methods 
Hormone-sensitive human MCF7 breast cancer cell line. The MCF7 
cell line was obtained from the pleural effusion of a patient with dis- 
seminated mammary carcinoma (Soule et al. 1973) and was ob- 
tained from the American Type Culture Collection, Rockville, 
USA. Cell line banking and quality control were performed accord- 
ing to the "seed stock concept" reviewed by Hay (1988). The cells 
were maintained inEagle's minimum essential medium (Sigma) con- 
taining NaHCO3 (2 g/l), gentamicin (50 mg/l), 10% fetal calf serum 
(Gibco) in 75-cm 2flasks at 37 ~ C in a H20-saturated atmosphere of
95% air and 5% CO2. The cells were serially passaged weekly fol- 
lowing trypsinization using trypsin/EDTA (Boehringer). For 
chemosensitivity testing the cells (in passage 155) were plated in 96- 
well microplates (100 pl/well) at a deusity of about 19 cells/micro- 
scopic field (Leitz Diavert, 320 • ) and were allowed to attach. After 
73.5 h, the medium was removed by suction and replaced with fresh 
medium (200 ~d/well) containing the drug (drugs were added as a 
1000-fold stock solution in dimethylformamide or pure solvent. On 
every plate the rows 5 and 6 (n = 16) acted as controls, whereas two 
vertical rows (n = 16) per drug concentration a d time point were 
used. After varying times of incubation the cells were fixed with glu- 
taraldehyde and stored under phosphate-buffered saline at 4 ~ C. All 
plates were stained with crystal violet simultaneously. The pro- 
cessing procedure and data anatysis were performed as described by 
Reile et al. (1990a). Drug effects were calculated as corrected TIC 
values according to: TIC ..... : (T-- Co)/(C-- Co)" 1001%], where T 
is the absorbance of treated cells, C that of the controls and Co 
the absorbancc at the time (t=0) when drug was added. The 
calculated experimental crrors for TIC ..... (according to the 
Gaussian formula) amount to about 10% after prolonged in- 
cubation. 
( - )-l,2-Bis (4-fluorophenyl) ethylenediaminedihydrochloride 
[(-) lOa.2HCl].  This was obtained as colorless crystals, re.p. 
240.5-241.5"C (decomp.), yield 78%, 21_  [oE]546-- 46, C= 1.0, 
MeOH. 
[( ++ )-l,2-Bis(4-fluorophenyl)ethylenediamine] dichloroplatinum(II) 
(8), method C. Synthesis has been described by Miiller et al. (1989). 
[ ( + )- 1,2-Bis (4-fluorophenyl) ethylenediamine] dichloroplatinum (II)
(( + ) 9). Compound ( + ) 9 was obtained as a yellow powder, yield 
86%, [c~]~26 = + 148, c=0.5, dimethylformamide. 
[ ( - )-l,2-Bis (4-fluorophenyl) ethylenediamine] dichloroplatinum (Il) 
( ( - )  10). Compound ((-)10) was a yellow powder, yield 88%, 
22 = [oE]87 -- 144, e=0.5, dimethylformamide. 
P388 Leukemia. The P388 leukemia (Dawe and Potter 1957; Geran 
et al. 1972) was maintained by routine passage in female DBA/2 
mice (Charles River Wiga, Sulzfetd, FRG). For determination f 
antitumor activity, female CDF1 mice (18-22 g, Zentralinstitut ffir 
Versuchstiere Hannover, FRG), were inoculated i.p. with 106 leu- 
kemia cells in 0.1 ml phosphate-buffered saline (day 0). The animals 
were randomly assigned to groups of six (ten animals to the solvent 
control) and the complexes were administered i.p. on days 1-9 as a 
solution or suspension in polyethylenegtycol-400/1.8% NaC1 in 
H20 (1 : 1). The antitumor activity was evaluated as median survival 
time (days) compared to the untreated control. 
Results and discussion 
CD spectra 
The spectra were obtained with a JASCO J-40 A spectropolarimeter 
(time constant 4 s; scan speed 50 nm/min) and recored in Me2SO at 
room temperature in 0.2 cm quartz cells. The concentrations were 
0.7 mMfor (+)9, and 0.8 mMfor ( -)10,  2 mM for (S,S)-dichloro- 
[1,2-diphenylethylenediamine]platinum(II) and 4 mM for (R,R)-di- 
chloro[1,2-diphenylethylenediamine]platinum(II). 
General procedures 
Melting points (uncorrected) were recorded in a Btichi 510 melting- 
point apparatus, 1H-NMR spectra with a Varian EM 360 L (60 
The strong effect o f  the d iastereomeric  [1,2-bis(4-f luoro- 
pheny l )e thy lened iamine]p la t inum( I I )  complexes found 
on the hormone-dependent  MXT mammary  carc inoma 
of  the mouse,  was reevaluated in the exper iment  on  the 
hormone-sens i t ive  human MCF7 breast  cancer cell l ine 
by means  of  the d ich lo rop la t inum( I I )  derivatives 7-10 
(Fig. 2). 
In  this test we studied the growth kinetics in the pres- 
ence of  increas ing drug concent rat ions  (0.5 gM,  1 I-tM, 
and  5 pM)  by sta in ing with crystal violet. A microcom-  
puter  technique,  which al lows a large number  of  spectro- 
photometr i c  measurements  necessary for the construc-  
t ion of  the growth curves, was used. In order to provide 
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Fig. 2. Effect of compounds 7-10 and of cisplatin on MCF7 breast 
cancer cell line; plot of corrected TIC values versus time of drug ex- 
posure, zx, 0.5 laM," o, 1 gM; n, 5 gM 
rected TIC values versus time of drug exposure. A 
gradual decrease of TIC ..... values with time indicates an 
inhibition of cell growth (i.e. a slowing down or a cessa- 
tion ofcell proliferation = cytostatic drug action). An in- 
crease of TIC ..... values with time of drug exposure 
represents primary drug resistance or recovery of the cells 
from drug-induced amage, which may result in full 
reproductive integrity of the cells (see also Mfiller et al. 
1990). TIC ..... values < 0 indicate cytocidal drug action. 
437 
On the MCF7 breast cancer cell line, the R, S-config- 
urated complex (7) shows a similar effect to cisplatin in 
a concentration of 1 pM and 5 pM. At the lowest concen- 
tration (0.5 gM) the cells are weakly inhibited initially 
but recover after about 150 h of drug exposure. This be- 
havior can be explained by a development of resistance of 
the cell line against low concentrations of 7. In the case 
of the more active complex 8, with the R,R/S,S configu- 
ration, a clearcut dose-dependent i hibition is observed, 
producing a cytocidal effect in the highest concentration 
(5 gM). Surprisingly, neither of the enantiomers (9 and 
10) was more active than the racemate (8). 
On the P388 leukemia of the mouse the enantio- 
meric [1,2-bis(4-fluorophenyl)ethylenediamine]dichloro- 
platinum(II) complexes (9 and 10) showed a strong but 
not dose-dependent inhibition of tumor growth, which 
probably results from their low water solubility (Table 3, 
compare also Reile et al. 1990 c). In accordance with the 
results on the MCF7 breast cancer cell line, differences in 
activity between the two enantiomers (9and 10) were not 
detectable. Further on, the antileukemic effect of 9 and 10 
is similar to that of their racemate 8. 
Differences in the antitumor activity of R,R- and S,S- 
configurated [1,2-diphenylethylenediamine]platinum (II) 
complexes due to the chirality of DNA were postulated 
for the first time by Gulotti and coworkers (1982, 1984), 
but could not be proved so far in experiments on the P388 
leukemia of the mouse. In contrast o these results Noji 
and coworkers (1984) reported on a different activity 
of enantiomeric [diaqua]l,2-diphenylethylenediamine] 
platinum(II) sulfates and nitrates in the L1210 mouse 
leukemia experiment. However, the significance of these 
data is questionable, since the order of activity changed 
depending on the nature of the counter ion. In the more 
meaningful in vitro experiment on the human MDA-  
MB231 breast cancer cell line we observed equal effects 
with both enantiomers of dichloro[1,2-diphenylethyl- 
enediamine]platinum(II), but marked differences be- 
tween diastereomers (Wappes et al. 1984 b). The complex 
with the R,R/S,S configuration was more active than its 
R,S counterpart. 
However, small differences we observed with enantio- 
meric 3- and 4-hydroxy-substituted dichloro[1,2-di- 
phenylethylenediamine]platinum(II) complexes (compare 
formulae of compounds 5 and 6) (Wappes et al. 1984a; 
Table 3. Antitumor effect of R,R- and S,S-configurated [1,2-bis(4-fluorophenyl)ethytenediamine]dichloroplatinum(II), compounds 9 and 10, 
on the P388 leukemia of the CDF I mouse 
Compound Total dose" Change ofmean body weight (g) Median survival TIC 
(pmol/kg) days (range) (%) 




0.3 4.7 - 9.0 (9 11) 100 
160 -0.9 -2.3 4.0 19.0 (17-22) 211 
120 -1.3 -1.4 19.5 (5oE0) 217 
60 0.2 -0.7 - 17.5 (17-20) 194 
160 -1.1 -1.2 3.9 18.5 (16-19) 206 
120 -0.3 -0.7 - 17.5 (16-20) 194 
60 -0.7 -0.3 - 16.5 (15-19) 183 
" The compounds were administered intraperitoneally aspolyethylcne-glycol-400/l.8% NaC1 solution on days 1-9 
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Jennerwein et al. 1989 b). The influence of  steric factors 
on the ant i tumor  activity of  p lat inum complexes is thor- 
oughly discussed in von Angerer  et al. (1989). 
Though the enant iomeric  [1,2-bis(4-f luorophenyl) 
ethylenediamine]dichloroplat inum(I I )  complexes 9 and 
10 show no difference in activity on the MCF7 breast 
cancer cetl line, it is conceivable that under in vivo condi-  
t ions the biological  effects o f  the enant iomers 9 and 10 
are different, since the discussed estrogen- and proges- 
terone- lowering effects of  these drugs (compare M/i l ler 
et al. 1989) also influence the hormone-dependent  
mammary  carc inoma. The steric factors are supposed to 
be more important  for the activity of  the enant iomeric  
[1,2-bis(4-f luorophenyl)ethylenediamine]dichloro- 
p lat inum(I I )  complexes on the steroid biosynthesis than 
on the DNA repl ication. 
Whether  enant iomeric  [1,2-bis(4-f luorophenyl)ethyl- 
enediamine]dichloroplat inum(I I )  complexes have differ- 
ing effects on the hormone-dependent  mammary  carci- 
noma in vivo will be studied on the estrogen-receptor-  
posit ive MXT mammary  carc inoma of  the mouse. 
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